A Multiple Dose Study of BAY1834845 in Healthy Male Subjects and in Patients With Psoriasis
Status:
Completed
Trial end date:
2021-02-05
Target enrollment:
Participant gender:
Summary
To assess safety and tolerability of multiple oral doses of BAY1834845 in healthy male
subjects (Part 1) and in patients with psoriasis (Part 2).
To assess the pharmacokinetic (PK) properties of total BAY1834845 in plasma after oral
multiple doses of BAY1834845 in healthy male subjects (Part 1) and patients with psoriasis
(Part 2).